IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3...
IceCure Medical Ltd. - Ordinary Shares (ICCM)
Company Research
Source: PR Newswire
Conference call to be held today at 10:00 am Eastern Time; Focus on U.S. market for ProSense® in breast cancer indicationCAESAREA, Israel, April 3, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported sales as of and for the twelve months ended December 31, 2023 increased 26% compared to the twelve months ended December 31, 2022, as the Company continues to transition from a research and development and clinical phase company to a commercial phase company.2023 Key Financial Highlights:Product sales globally rose 26%Product sales in the U.S. grew 24%Cash and cash equivalents of $11.1 million at December 31, 2023During the first quarter of 2024, the Company raised $3 million in gross proceeds from the sale of ordinary shares under its At-the-Market ("ATM") offering facility, ending t
Show less
Read more
Impact Snapshot
Event Time:
ICCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ICCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ICCM alerts
High impacting IceCure Medical Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ICCM
News
- IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA [Yahoo! Finance]Yahoo! Finance
- IceCure Medical Ltd (NASDAQ: ICCM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.MarketBeat
- IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer [Yahoo! FinaYahoo! Fina
- IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast CancerPR Newswire
- IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
ICCM
Earnings
- 5/22/23 - Beat
ICCM
Sec Filings
- 4/15/24 - Form 6-K
- 4/15/24 - Form 6-K
- 4/3/24 - Form 6-K
- ICCM's page on the SEC website